COVID-19 Diagnostics Market By Product (Instruments and Reagents & Kits), By Sample Type (Oropharyngeal & Nasopharyngeal Swabs, Blood, Urine, and Others), By Technology (Polymerase Chain Reaction (PCR), Antibody or Enzyme-Linked Immunosorbent Assay (ELISA), Serology, Portable or Point-of-Care (POC), and Others), By End-user (Laboratories, Hospitals, Diagnostic Centres & Clinics, and Research Institutes), and By Region - Trends, Analysis and Forecast till 2034

The COVID-19 diagnostics market is divided into five regions: Latin America, North America, Europe, Asia Pacific, and the Middle East and Africa. With a 40% market share in 2020, Europe is not just leading but also shaping the target market for COVID-19 diagnostics. This is due to high levels of awareness regarding the identification, transmission, and efficient treatment of coronavirus infections. The EUA was granted to Novacyt Group, a clinical diagnostics firm based in France, for its 2-hour coronavirus test in March 2020. This has significantly improved the approvals of diagnostic products, solidifying Europe's dominance in the market share in 2020. Furthermore, in April 2020, Abbott was granted CE clearance for their IgG serology blood test for coronavirus. Additionally, growth in Asia Pacific is expected to be the fastest in the upcoming years, due to the quantity of recent arrivals offering COVID-19 diagnostic services. For example, Mylab Discovery Solutions, the first Company in India, received approval for their Mylab PathoDetect COVID-19 qualitative PCR kit in March 2020.